Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.

Luigi GargiuloLuciano IbbaGiulia PaviaCarlo Alberto VignoliFrancesco PiscazziMario ValentiFederica SannaChiara PeruginiJessica AvaglianoAntonio CostanzoAlessandra Narcisi

Published in: Dermatology and therapy (2022)

Our findings confirmed that risankizumab is a safe and effective therapeutic option for the treatment of a wide "real-life" cohort of patients with psoriasis.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
prognostic factors
coronary artery disease
high intensity
clinical trial
patient reported outcomes
study protocol
smoking cessation